Johnson & Johnson to Acquire Atraverse Medical

Why It Matters

The deal expands J&J’s cardiovascular device suite, strengthening its position in the fast‑growing AFib ablation market and leveraging Atraverse’s proven technology. It also accelerates J&J’s growth trajectory amid rising demand for minimally invasive cardiac therapies.

Key Takeaways

• Atraverse's Hotwire used in ~3,000 left‑heart procedures.
• 29% of procedures performed without fluoroscopy.
• J&J's cardiovascular unit sales rose 13% to $2.38 B Q1.
• Hotwire adds RF guidewire to J&J's growing portfolio.
• Deal value undisclosed; closing expected Q2 2026.

Pulse Analysis

The global burden of atrial fibrillation continues to climb, with an estimated 6 million Americans diagnosed and demand for catheter‑based ablation rising sharply. Radio‑frequency (RF) guidewires have become a cornerstone of minimally invasive procedures, offering precise energy delivery while reducing procedure time. Boston Scientific’s ProTrack RF Anchor Wire set the benchmark, but newer entrants like Atraverse’s Hotwire are pushing the envelope with smaller diameters and enhanced tip visibility. As hospitals seek to lower radiation exposure, devices that enable fluoroscopy‑free navigation are gaining clinical favor.

Atraverse Medical was founded by the team behind Farapulse, the pulsed‑field ablation pioneer acquired by Boston Scientific in 2021. Leveraging that expertise, Atraverse secured FDA clearance for Hotwire in 2024 after raising $12.5 million, followed by a $29.4 million round to scale commercialization. To date, nearly 100 electrophysiologists have used Hotwire in almost 3,000 left‑heart access cases, achieving a 100% procedural success rate in a multicenter first‑in‑human study of 500 patients. Notably, 29% of those procedures were completed without fluoroscopy, underscoring the device’s potential to reduce radiation risk.

J&J’s acquisition of Atraverse dovetails with its recent cardiovascular expansion, which saw unit revenue climb 13% to $2.38 billion in Q1, driven by acquisitions such as Abiomed’s Impella and Shockwave Medical’s intravascular lithotripsy platform. By adding Hotwire’s RF guidewire, J&J gains a differentiated tool that complements its existing electrophysiology and structural heart offerings, potentially increasing cross‑sell opportunities and market share against rivals like Boston Scientific and Medtronic. Although the purchase price remains undisclosed, analysts expect the deal to be accretive, reinforcing J&J’s strategy to dominate the high‑growth AFib ablation space and deliver long‑term shareholder value.

Deal Summary

Johnson & Johnson announced it will acquire Atraverse Medical, a developer of the FDA‑cleared Hotwire radio‑frequency guidewire for atrial fibrillation ablation. The deal value was not disclosed, and J&J expects to close the transaction in the second quarter of 2026. Atraverse’s technology will expand J&J’s cardiovascular portfolio.